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Objective: To investigate how carboxyhaemoglobin concentration is related to smoking habit and to
assess whether carboxyhaemoglobin concentration is related to mortality.
Design: Prospective cohort study.
Setting: Residents of the towns of Renfrew and Paisley in Scotland.
Participants: The whole Renfrew/Paisley study, conducted between 1972 and 1976, consisted of 7048
men and 8354 women aged 45–64 years. This study was based on 3372 men and 4192 women who
were screened after the measurement of carboxyhaemoglobin concentration was introduced about
halfway through the study.
Main outcome measures: Deaths from coronary heart disease (CHD), stroke, chronic obstructive
pulmonary disease (COPD), lung cancer, and all causes in 25 years after screening.
Results: Carboxyhaemoglobin concentration was related to self reported smoking and for each smoking
category was higher in participants who reported inhaling than in those who reported not inhaling.
Carboxyhaemoglobin concentration was positively related to all causes of mortality analysed (relative
rates associated with a 1 SD (2.93) increase in carboxyhaemoglobin for all causes, CHD, stroke, COPD,
and lung cancer were 1.26 (95% confidence interval (CI) 1.19 to 1.34), 1.19 (95% CI 1.13 to 1.26), 1.19
(95% CI 1.13 to 1.26), 1.64 (95% CI 1.47 to 1.84), and 1.69 (95% CI 1.60 to 1.79), respectively).
Adjustment for self reported cigarette smoking attenuated the associations but they remained relatively
strong.
Conclusions: Self reported smoking data were validated by the objective measure of carboxyhaemoglobin
concentration. Since carboxyhaemoglobin concentration remained associated with mortality after
adjustment for smoking, carboxyhaemoglobin seems to capture more of the risk associated with smoking
tobacco than does self reported tobacco consumption alone. Analysing mortality by self reported cigarette
smoking underestimates the strength of association between smoking and mortality.
E
pidemiological studies often suffer from underreporting
of habits known to be unhealthy or undesirable. In
particular, the validity of self reported smoking has been
questioned. Studies have used physical measures such as
cotinine1 2 (in blood, urine, or saliva) or carboxyhaemoglo-
bin3 4 to validate self reported smoking habit. The NHANES II
(Second National Health And Nutrition Examination Survey)
used carboxyhaemoglobin measurements to investigate bias
towards reporting multiples of 10 cigarettes a day.4 The BUPA
study found positive relationships between carboxyhaemo-
globin and the amount smoked and amount inhaled.5 In this
study, carboxyhaemoglobin was used to investigate the
relationship with smoking habits and to see how carboxy-
haemoglobin concentration is related to mortality from
various diseases in the 25 years after screening.
METHODS
The Renfrew/Paisley study was a general population pro-
spective cohort study conducted between 1972 and 1976 on
residents of the towns of Renfrew and Paisley in Scotland.6
These towns are located near the city of Glasgow in Scotland
and are areas of high socioeconomic deprivation with life
expectancy figures among the worst in the whole of the UK.7
Men and women aged between 45–64 years were invited to
take part. The response rate of 78% resulted in 7048 male and
8354 female participants.
Participants completed a questionnaire and attended a
clinical examination at specially set up screening centres. The
questionnaire asked about smoking habit, from which
smoking categories were derived. These were never smoked,
smoked only cigars or a pipe, smoked cigarettes (1–5, 6–14,
15–24, or 25 or more a day) or smoked in the past. Former
smokers were defined as not having smoked for at least 12
months before screening; otherwise, they were categorised as
current smokers. Current smokers were also asked whether
they inhaled. At the screening examination, height was
measured without shoes and the forced expiratory volume in
one second (FEV1) was measured with a vitalograph
spirometer with the subject standing.8 Predicted FEV1 was
calculated from equations derived from a healthy subset of
the population for age, height, and sex.8 Adjusted FEV1 was
calculated as a percentage of actual FEV1 to predicted FEV1.
In 1975, about halfway through the Renfrew/Paisley study,
co-oximeter measurement of carboxyhaemoglobin concen-
tration in the participants’ blood was introduced.
Mortality details are received routinely from the flagging
system at the National Health Service Central Register in
Edinburgh, the normal method for UK cohort studies.
Additionally, death data were obtained from a computerised
linkage with deaths in Scotland. For this study, deaths
occurring in the 25 year period after screening were defined
Abbreviations: CHD, coronary heart disease; COPD, chronic
obstructive pulmonary disease; FEV1, forced expiratory volume in one
second; ICD-9, International classification of diseases, ninth revision;
NHANES II, Second National Health And Nutrition Examination Survey
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as being caused by coronary heart disease (CHD)
(International classification of diseases, ninth revision (ICD-9)
codes 410–414), stroke (codes 430–438), chronic obstructive
pulmonary disease (COPD) (codes 490–494 and 496), and
lung cancer (code 162). Deaths from all causes are also
reported.
After the carboxyhaemoglobin measurement was intro-
duced, 7809 participants were screened. Of these, 229 had
missing values of carboxyhaemoglobin and there was one
obvious outlier. Also excluded from this study were nine
participants with missing data on adjusted FEV1 and six
participants who had embarked from the UK during the
follow up period. Therefore the complete data of 3372 men
and 4192 women (total 7564) were analysed. Trends of
carboxyhaemoglobin concentration by amount smoked were
calculated by regression analysis for never and current
cigarette smokers based on the number of cigarettes smoked
a day. Differences between mean carboxyhaemoglobin
concentration by inhalation were calculated by using t tests.
Means of adjusted FEV1 by quintile of carboxyhaemoglobin
were additionally adjusted for smoking with PROC GLM in
SAS/STAT, version 6 (SAS Institute, Cary, North Carolina,
USA). The smoking adjustment was entered as the number of
cigarettes smoked daily by current cigarette smokers, with
zero allocated to non-smokers and former cigarette smokers.
Trends for adjusted FEV1 with carboxyhaemoglobin were
calculated by linear regression analysis. Cox’s proportional
hazards models were used to estimate relative rates of
mortality by quintile of carboxyhaemoglobin and to calculate
the relative rate associated with a one standard deviation
increase in carboxyhaemoglobin concentration with carbox-
yhaemoglobin as a continuous variable. Adjustments were
made for smoking by adding the number of cigarettes
smoked daily for current and former smokers, with an
additional variable for former smokers (1 if former smoker, 0
otherwise). Cox’s models were also used for estimating the
relative rates of mortality by smoking category, with
adjustments made for carboxyhaemoglobin concentration.
RESULTS
Table 1 presents the mean carboxyhaemoglobin concentra-
tion for each smoking category. Never smokers had the
lowest carboxyhaemoglobin concentration followed by for-
mer smokers. A dose response relationship was seen with
number of cigarettes smoked a day, with the pipe or cigar
smokers having a mean carboxyhaemoglobin concentration
between the 1–5 and the 6–14 cigarettes a day categories.
Results were consistent for men and women.
The majority of cigarette smokers reported inhaling (93% of
men and 82% of women). For each smoking category and for
each sex, inhalers had higher carboxyhaemoglobin concentra-
tions than non-inhalers (table 2). Adjusting for number of
cigarettes smoked did not affect the difference in carboxyhae-
moglobin concentration between inhalers and non-inhalers
(not shown). Overall, among current smokers, inhalers had a
mean adjusted carboxyhaemoglobin concentration of 5.63
compared with 4.40 for non-inhalers (p , 0.0001).
Carboxyhaemoglobin was strongly related to adjusted
FEV1 in men and women (table 3). Participants with lower
carboxyhaemoglobin concentrations had higher adjusted




No Mean (SD) No Mean (SD) No Mean (SD)
Never 2448 1.59 (1.72) 547 1.77 (1.72) 1901 1.53 (1.71)
Former 1206 1.96 (1.87) 876 2.09 (1.94) 330 1.62 (1.64)
Pipe or cigar 91 2.63 (2.62) 86 2.52 (2.60) 5 4.42 (2.53)
Cigarettes/day
1–5 162 2.31 (1.94) 36 2.19 (1.58) 126 2.34 (2.03)
6–14 1002 4.39 (2.48) 368 4.13 (2.30) 634 4.54 (2.57)
15–24 1945 5.68 (2.64) 921 5.48 (2.63) 1024 5.86 (2.64)
>25 710 6.02 (2.86) 538 5.95 (2.84) 172 6.23 (2.90)
All 7564 3.52 (2.93)* 3372 3.81 (2.90)* 4192 3.27 (2.93)*
*p,0.0001 for never and current cigarette smokers.
Table 2 Mean carboxyhaemoglobin percentage for current cigarette smokers according
to whether they inhale (1709 men and 1863 women)
Smoking (cigarettes/day)
All Men Women
No Mean (SD) No Mean (SD) No Mean (SD)
1–5
Inhale 87 2.46 (2.10) 26 2.43 (1.69) 61 2.48 (2.26)
Not inhale 67 2.07 (1.65) 9 1.64 (1.15) 58 2.13 (1.71)
p Value 0.20 0.21 0.35
6–14
Inhale 767 4.67 (2.42) 303 4.40 (2.28) 464 4.84 (2.49)
Not inhale 180 3.96 (2.46) 38 3.30 (1.77) 142 4.13 (2.59)
p Value ,0.0001 0.004 0.004
15–24
Inhale 1670 5.98 (2.53) 815 5.75 (2.53) 855 6.21 (2.51)
Not inhale 174 4.56 (2.39) 48 4.38 (2.34) 126 4.63 (2.41)
p Value ,0.0001 ,0.0001 ,0.0001
>25
Inhale 583 6.63 (2.58) 445 6.59 (2.53) 138 6.77 (2.74)
Not inhale 44 5.25 (2.20) 25 5.0 (2.30) 19 5.56 (2.08)
p Value 0.001 0.002 0.07
p Value for difference in means.
322 Hart, Smith, Hole, et al
www.heartjnl.com
 on 30 October 2006 heart.bmjjournals.comDownloaded from 
FEV1 and trends were significant even after adjustment for
cigarette smoking.
Carboxyhaemoglobin concentration was positively related
to all cause mortality, adjusted for age and sex (table 4).
Adjustment for smoking considerably attenuated the asso-
ciations but they remained relatively strong. Relationships
with CHD mortality were similar. A less clear relationship
was seen between carboxyhaemoglobin and stroke and this
was attenuated after adjustment for smoking. Strong
relationships were seen with COPD mortality, including after
adjustment for smoking, although smaller numbers produced
large confidence intervals. Carboxyhaemoglobin concentra-
tion was strongly related to lung cancer mortality, even after
adjustment for smoking. Tests for interactions between sex
and carboxyhaemoglobin concentration were not significant
for any of the causes of death analysed (all cause p = 0.10,
CHD p = 0.08, stroke p = 0.57, COPD p = 0.09, and lung
cancer p = 0.30). When data were analysed by smoking
category, the positive relationships with mortality were
similarly attenuated when adjusted for carboxyhaemoglobin
concentration (not shown).
DISCUSSION
This analysis has validated the self reported smoking habits
in the Renfrew/Paisley cohort by an objective measure.
Carboxyhaemoglobin concentrations were strongly related
to self reported smoking levels, self reported inhalation, and
respiratory function and in addition were related to various
causes of death, even after adjustment for smoking.
Since carboxyhaemoglobin concentration is a physical
measurement, it can be considered a proxy for risk of disease
caused by smoking. In a study of about 1000 Swedish middle
aged men, morning carboxyhaemoglobin concentrations
were measured.9 Concentrations were low for both non-
smokers and former smokers. Higher concentrations were
reported for current smokers and there was a dose-response
relationship as normal daily consumption increased. A large
variation in carboxyhaemoglobin concentration was seen
Table 3 Mean adjusted forced expiratory volume in one second percentage unadjusted and adjusted for smoking (cigarettes/
day) by quintile of carboxyhaemoglobin (COHb) among men and women in the Renfrew/Paisley study
Quintile COHb
All Men Women
No Unadjusted Adjusted No Unadjusted Adjusted No Unadjusted Adjusted
1 (0.1–0.8) 1512 92.2 94.3 533 90.3 92.8 979 93.6 95.2
2 (0.9–2.0) 1622 92.1 93.8 630 89.9 91.8 992 93.7 95.1
3 (2.1–3.7) 1454 89.5 90.0 729 88.1 89.0 725 90.8 91.1
4 (3.8–6.1) 1466 88.5 86.7 738 86.2 84.6 728 90.6 88.8
5 (6.2–24.2) 1510 87.1 84.4 742 86.8 84.2 768 87.0 84.6
p for trend ,0.0001 ,0.0001 0.007 ,0.0001 ,0.0001 ,0.0001
Table 4 Relative rates (RR) and 95% confidence intervals of all cause, coronary heart
disease (CHD), stroke, chronic obstructive pulmonary disease (COPD), and lung cancer
mortality over 25 years by quintile of carboxyhaemoglobin (COHb) and per standard
deviation increase in COHb in men and women in the Renfrew/Paisley study
COHb quintile (range) No of deaths Model 1* Model 2
All causes 1 (0.1–0.8) 686 1 1
2 (0.9–2.0) 727 0.97 (0.88 to 1.08) 0.95 (0.85 to 1.05)
3 (2.1–3.7) 764 1.22 (1.10 to 1.35) 1.13 (1.01 to 1.25)
4 (3.8–6.1) 863 1.54 (1.39 to 1.71) 1.28 (1.15 to 1.43)
5 (6.2–24.2) 942 1.77 (1.60 to 1.95) 1.41 (1.26 to 1.57)
RR associated with 1 SD increase in COHb 1.26 (1.19 to 1.34) 1.16 (1.09 to 1.23)
CHD 1 (0.1–0.8) 213 1 1
2 (0.9–2.0) 247 1.05 (0.87 to 1.26) 1.03 (0.86 to 1.24)
3 (2.1–3.7) 276 1.35 (1.13 to 1.62) 1.28 (1.06 to 1.53)
4 (3.8–6.1) 253 1.37 (1.14 to 1.65) 1.20 (0.98 to 1.46)
5 (6.2–24.2) 280 1.59 (1.33 to 1.90) 1.34 (1.09 to 1.64)
RR associated with 1 SD increase in COHb 1.19 (1.13 to 1.26) 1.12 (1.06 to 1.19)
Stroke 1 (0.1–0.8) 106 1 1
2 (0.9–2.0) 86 0.76 (0.57 to 1.01) 0.74 (0.56 to 0.99)
3 (2.1–3.7) 100 1.13 (0.86 to 1.49) 1.05 (0.79 to 1.38)
4 (3.8–6.1) 107 1.41 (1.08 to 1.85) 1.18 (0.88 to 1.59)
5 (6.2–24.2) 89 1.28 (0.96 to 1.70) 1.03 (0.74 to 1.42)
RR associated with 1 SD increase in COHb 1.19 (1.13 to 1.26) 1.09 (0.97 to 1.22)
COPD 1 (0.1–0.8) 12 1 1
2 (0.9–2.0) 16 1.22 (0.58 to 2.57) 1.15 (0.54 to 2.43)
3 (2.1–3.7) 24 2.16 (1.08 to 4.33) 1.90 (0.94 to 3.84)
4 (3.8–6.1) 50 5.10 (2.71 to 9.60) 3.94 (2.03 to 7.66)
5 (6.2–24.2) 57 6.17 (3.30 to 11.54) 4.42 (2.23 to 8.67)
RR associated with 1 SD increase in COHb 1.64 (1.47 to 1.84) 1.46 (1.23 to 1.74)
Lung cancer 1 (0.1–0.8) 34 1 1
2 (0.9–2.0) 26 0.69 (0.41 to 1.15) 0.64 (0.38 to 1.06)
3 (2.1–3.7) 61 1.82 (1.20 to 2.77) 1.43 (0.93 to 2.19)
4 (3.8–6.1) 109 3.57 (2.43 to 5.26) 2.14 (1.43 to 3.23)
5 (6.2–24.2) 159 5.41 (3.73 to 7.85) 2.89 (1.92 to 4.34)
RR associated with 1 SD increase in COHb 1.69 (1.60 to 1.79) 1.42 (1.27 to 1.59)
1 SD = 2.93%.
*Model 1 adjusts for age and sex; model 2 adjusts for age, sex, and smoking.
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among people who reported smoking the same amount daily.
It was suggested that prospective studies are required to see
whether carboxyhaemoglobin measurement is a better
measurement than tobacco consumption by questionnaire.
NHANES II found a bias towards reporting the daily
amount smoked in multiples of 10 cigarettes a day, which
could have been systematic (that is, rounding down) or
random.4 No similar pattern was seen for carboxyhaemoglo-
bin concentration. It was suggested that biochemical
verification and self reported smoking level could be
combined when examining smoking–disease relationships.
It was also suggested that, since there were errors in self
reported smoking, reported relationships between smoking
and disease may not have been accurate.
In addition to finding positive relationships between
carboxyhaemoglobin and amount smoked, the BUPA study
found that carboxyhaemoglobin was related to the risk of
mortality from CHD, lung cancer, or chronic obstructive lung
disease (defined as ICD-9 codes 416, 491, 492, 496, and 519)
independently of smoking category or amount smoked.5
Analysis by smoking after adjustment for carboxyhaemoglo-
bin removed the smoking–disease relationship. In the current
study, carboxyhaemoglobin concentration remained asso-
ciated with mortality after adjustment for smoking, suggest-
ing that carboxyhaemoglobin is capturing more smoking
related risk than is just self reported smoking. Examples may
be unmeasured differences in the way the cigarettes were
smoked, such as number of puffs for each cigarette, smoking
right down to the butt, or depth of inhalation. The
carboxyhaemoglobin concentration could also have been
affected by passive smoking, which could have had an
increased effect on mortality risk.
Experiments involving smokers showed that carboxyhae-
moglobin concentration did not increase during the day as
more cigarettes were smoked but remained around each
person’s mean value.10 Implications for the current study are
that time of day of screening or time since the last cigarette was
smoked would not affect the carboxyhaemoglobin concentra-
tion measured. The strong relationship between carboxyhae-
moglobin and lung function was to be expected, since carbon
monoxide is removed from the body by expiration and
expiration is less efficient in people with poorer lung function.11
It is known that cigarette smokers who report not inhaling
still have raised carboxyhaemoglobin concentrations.3
However, these concentrations are lower than for reported
inhalers. In the current study, from a validation viewpoint,
carboxyhaemoglobin concentrations were consistently lower
in non-inhalers than in inhalers. Further studies of passive
smoking in this cohort will be able to use carboxyhaemoglo-
bin concentration to exclude participants who may have
misreported their smoking habits.12
This research suggests that the smoking mortality risk may
have previously been underestimated due to misreporting of
cigarette consumption. Carboxyhaemoglobin concentration
may be picking up unmeasured risk in several ways. Firstly,
participants could have underreported their tobacco con-
sumption through rounding their response to a pack size or
giving an incorrect reply because they know that smoking is
harmful. Secondly, carboxyhaemoglobin concentration may
be a better measure than just number smoked of the harmful
effects of cigarettes, since it is capturing additional unmea-
sured effects such as depth of inhalation and how much of
each cigarette is smoked. In consequence in prospective
epidemiological studies the proportion of mortality attributed
to smoking in a population would be underestimated through
applying the associations observed between reported smok-
ing and mortality.
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